Evaluating a new approach for treatment-resistant depression
Chronic Anergic-anhedonic Depression Open Trial
This study is testing a new treatment plan for people with treatment-resistant depression to see if it helps them feel better in everyday care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06110507 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on a specific type of depression known as dopamine-sensitive anergic-anhedonic syndrome, which often does not respond to standard treatments. The study aims to assess the feasibility and effectiveness of a new treatment algorithm called DATA, which involves using non-selective monoamine oxidase inhibitors or dopamine D2 receptor agonists. Patients receiving care at a specialized center for resistant depression will be evaluated for both short and long-term outcomes. The study seeks to determine how well these recommendations work in routine clinical practice.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been diagnosed with treatment-resistant depression and are receiving care at the Expert Resistant Depression Center of Alsace.
Not a fit: Patients who have expressed opposition to participating in the study or are under judicial protection will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a new effective treatment option for patients suffering from treatment-resistant depression.
How similar studies have performed: While this approach is novel in evaluating the DATA recommendations in routine care, similar dopaminergic strategies have shown promise in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major patient (≥18 years old) * Man or woman * Patient covered for consultation at the Expert Resistant Depression Center of Alsace (CEDRA) (CHU-Strasbourg branch) for TRAD between 01 January 2013 and 31 March 2023 * Patient not opposing to the reuse of their data for the purposes of this research Exclusion Criteria: * Patient having expressed opposition to participating in the study * Patient under judicial protection * Patient under guardianship or curatorship
Where this trial is running
Strasbourg
- CENTRE DE NEUROMODULATION NON INVASIVE DE STRASBOURG (CEMNIS) - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Jack FOUCHER, MD, PhD
- Email: jack.foucher@chru-strasbourg.fr
- Phone: 33 3 88 11 69 21
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.